In Autosomal dominant retinitis pigmentosa, RHO-related (RHO, OMIM 613731), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the OFF well. The forced corrective direction is to lower s toward OFF branch (polarity: clear). Classification: ○ Novel direction-only lead. Direction only — no dose, no efficacy magnitude.
The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5416, γ 1.4719, spinodal 0.6873). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.
The emergence switch
The switch for Autosomal dominant retinitis pigmentosa, RHO-related is an R19 double-well emerged from the real proximal-promoter DNA of RHO. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.
emergent axis
↓ DOWN [F]
healthy branch
OFF
lesion
GOF
γ (stiffness)
1.4719
barrier
0.5416
spinodal
0.6873
s_on / s_off
1.2132 / -1.2132
fragility
0.26
corrective polarity
clear
forced direction
lower s toward OFF branch
Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.5416 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.
The derived corrective lever
The cusp forces a corrective direction: lower s toward OFF branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating RHO does NOT relieve the disease branch in a RHO model, the h-restore(clear) lever is refuted for this axis.
EXCLUDED: gain-of-function -- the lesion is not a destabilised healthy product to stiffen; the corrective move is to clear/oppose the toxic drive (h-restore)
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual RHO allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.
Agents mapped onto the lever
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Direction-only candidate leads (corpus join)
Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.
Mechanism. An investigational intravitreal antisense oligonucleotide that binds the mutant P23H RHO transcript and triggers RNase-H-mediated cleavage, allele-selectively lowering the dominant-negative rhodopsin product while sparing wild-type RHO. Direction on the disease axis: decrease -- clear the toxic gain-of-function product. Engaged node: RHO (unique among the 113). Allele scope: targets the P23H mutant allele (the most common adRP RHO allele in the US); other RHO gain-of-function alleles would need their own allele-selective agent. Addresses the honest-miss reason (no approved RHO-lowering agent). INVESTIGATIONAL direction-only hypothesis (no efficacy/approval/availability claim); status per training knowledge plus a 2026-06 web check (first-in-human Aurora study) -- confirm current development.
Prior-art. Direction-only hypothesis: the geometry derives a decrease (clear the toxic gain-of-function product) for the RHO GOF node; the investigational allele-selective antisense oligonucleotide QR-1123 lowers the mutant P23H rhodopsin transcript, a matched decrease, addressing the honest-miss reason (no approved RHO-lowering agent). First-in-human (Aurora, NCT04123626); P23H-allele-scoped. Investigational; confirm current status. No efficacy/availability claim.
Safety (qualitative; no magnitude). investigational intravitreal antisense oligonucleotide; ocular-delivery and target-engagement considerations (qualitative; no magnitude); early in-human programme -- confirm current development status
Falsifier. If QR-1123 (a gene-specific decrease agent) clearing/opposing the accumulating load does NOT relieve the DOWN [F] disease branch in a RHO model, the h-restore(clear) direction is refuted for QR-1123 here.
Source: QR-1123 (Ionis/ProQR) allele-selective RHO P23H knockdown antisense oligonucleotide; first-in-human Aurora study NCT04123626 in adRP
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.
Evidence & provenance
What is reproduced vs. cited for this page.
element
grade
basis
R19 switch & cusp geometry (this page)
[V] verified
emerged from measured promoter γ of RHO; deterministic, 2×sha256 identical
corrective direction
[F] forced
forced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads
[O] open
direction-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude
Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).